Study of CM310 in Patients With Allergic Rhinitis

Last updated: November 7, 2024
Sponsor: Keymed Biosciences Co.Ltd
Overall Status: Completed

Phase

2

Condition

Allergies & Asthma

Rhinitis, Allergic, Perennial

Common Cold

Treatment

CM310

Clinical Study ID

NCT05908721
CM310-107107
  • Ages 18-65
  • All Genders

Study Summary

This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female aged 18-65.

  • Understand the study and sign the Informed Consent Form voluntarily.

  • Take effective contraception measures throughout the study period.

Exclusion

Exclusion Criteria:

  • Used other investigational drugs.

  • Allergies to drugs with IL-4Rα monoclonal antibody or drug components of CM310.

  • Plan to participate in other studies during this clinical trial.

  • With malignant or benign tumors of the nasal cavity.

  • Other reasons the researcher believes that the subject is not suitable toparticipate in this study.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: CM310
Phase: 2
Study Start date:
August 23, 2023
Estimated Completion Date:
December 10, 2023

Study Description

Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.

Connect with a study center

  • Beijing Tong-Ren hospital

    Beijing,
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.